FOXP3 and neoplasm: Subcutaneous synergic mouse tumour model with intra-tumoural OV injection: Survival: significantly prolonged survival compared to parental OV and untreatedDisease control: significantly decreased tumour growth compared to parental OV and untreated; successful tumour rejection following rechallengeImmune response: significantly increased activated CD8+ T cell and reduced Foxp3+ Treg tumour infiltration; higher effector memory T cell: central memory T cell ratio for PD-1 (significant) and PD-L1 (not significant) OVs compared to untreated